The clinical trial is an international, multi-center, placebo-controlled study that will examine the effectiveness of SLC022 in controlling pain associated with post-herpetic neuralgia (PHN). Solace anticipates having results from the study in the second half of 2009.
Solace Pharmaceuticals has also established a two-year collaboration with professor Keith Channon of the department of cardiovascular medicine at the University of Oxford, UK. Dr Channon’s work complements Solace’s work in the development of small-molecule inhibitors of the BH4 pathway for treating chronic pain.
Eliot Forster, CEO of Solace, said: “The initiation of this study is another important milestone for Solace in our drive to discover and develop innovative treatments for pain.
“Our confidence in SLC022 is underpinned by a large body of prior preclinical and clinical data generated during the compound’s previous development in a non-pain indication. We believe these data lower the development risk and enhance the opportunity for a favorable clinical profile.”